retatrutide phase 3 trial dosage Eli Lilly's shows promising weight loss results in New GLP-3 drug significantly slashes

Tirzepatide works by targeting two specific receptors in your body: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

1 Despite growing adoption and inclusion in global guidelines recognizing obesity as a chronic disease requiring extended management, evidence on outcomes after cessation of GLP-1 therapy is limited and heterogeneous

We walk patients through what is actually available to them, not a single-script answer

Final Thoughts Retatrutide could be a major development in the world of weight loss treatments, offering a triple-action approach that may outperform existing medicines

Hazard ratios were also estimated using Cox-proportional hazard models

Important contraception consideration: Tirzepatide delays gastric emptying and can reduce the absorption of oral contraceptives